Clinical Trial Update: Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance and Type 2 Diabetes in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome [Phase 4]

View source ↗

Summary

Phase 4 trial indicates sitagliptin improved beta cell function and reduced progression to impaired glucose tolerance and type 2 diabetes in metformin-intoleran…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Impaired Glucose Tolerance
• Polycystic Ovary Syndrome
• Type 2 Diabetes Mellitus

Drugs mentioned

• Januvia (sitagliptin) (sitagliptin)

Snippet

Sponsor: University Medical Centre Ljubljana | Conditions: PCOS | Phase 4 | Status: COMPLETED